<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471510</url>
  </required_header>
  <id_info>
    <org_study_id>NEOSH101-CLIN-AGA004</org_study_id>
    <nct_id>NCT00471510</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neosil, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neosil, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of three doses of topical
      NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center
      of the scalp (Norwood/Hamilton grades III-IV androgenetic alopecia). Four equally sized
      treatment groups (35 men each) will receive either NEOSH101 0.5%, NEOSH101 1.0%, NEOSH101
      2.0% or placebo. A 12-week observation period will follow the treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair density, hair growth rate, hair diameter as measured using the Trichoscan method</measure>
    <time_frame>16 weeks application treatment period followed by 12 weeks observation period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment score of dermal tolerability</measure>
    <time_frame>16 weeks application treatment period followed by 12 weeks observation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment score</measure>
    <time_frame>16 weeks application treatment period followed by 12 weeks observation period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEOSH101 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEOSH101 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEOSH101 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetrapeptide aldehyde proteasome inhibitor (NEOSH101)</intervention_name>
    <description>Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men, aged 18 to 49 years, in general good health

          -  Norwood/Hamilton grades III - IV androgenetic alopecia, with thinning hair in the
             vertex area

        Exclusion Criteria:

          -  Concomitant dermatologic or medical condition(s) which may interfere with the
             investigator's ability to evaluate the subject's response to the study drug

          -  Treatment with a systemic or locally acting medication which may interfere with the
             study objectives, such as minoxidil treatment in the 6 months prior to study day 1,
             finasteride treatment in the 12 months prior to study day 1, or treatment with other
             investigational hair growth products in the 6 months prior to study day 1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Gassmueller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>bioskin Institute for Dermatological Research and Development GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>bioskin Institute for Dermatological Research and Development GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <last_update_submitted>May 16, 2008</last_update_submitted>
  <last_update_submitted_qc>May 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andria Langeberg, MD, Vice President, Clinical Development</name_title>
    <organization>Neosil, Inc.</organization>
  </responsible_party>
  <keyword>androgenetic alopecia</keyword>
  <keyword>male pattern hair loss</keyword>
  <keyword>male pattern baldness</keyword>
  <keyword>androgenetic alopecia or male pattern hair loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

